This is the third competitive renewal of our Program Project Grant. We have modified the name to reflect the refinement in focus, Antibody Targeted Radiation and Immunotherapy for the Treatment of Solid Tumors. There are three projects, 1) Radioimmunotherapy: clinical and radiobiologic studies, 2) pretargeting with anti-cea mabs for therapy, and 3) cea-targeted immunotherapeutics Project 1 exploits the most effective strategies we have developed for RIT of solid tumors, combining RIT with chemotherapy in the most appropriate clinical setting. Significant is the addition of a radiobiologic research component. Project 2 is a merger of our antibody engineering effort and the synthetic chemistry effort from the last PPG into a project which now clearly focuses on the development of clinically applicable pretargeting approaches. Project 3 represents a new project which has developed out of our previous work on engineering an anti-CEA-IL2 immunocytokine. The projects will be supported by the same six cores (Clinical Imaging, Radiopharmacy, Clinical Production, Animal Core, Biostatistics, and Administration) that have been the foundation for both the research and the clinical trials. There are a number of new key personnel on this application;Dr. Colcher, with over 25 years of experience with monoclonal antibodies, Dr. Yu with world renown expertise in molecular immunology, Dr. Radany with both clinical and research interests in radiobiology, Dr. Bading with over 25 years of imaging physics, Dr. Frankel providing excellent biostatistical support, Dr. Hudson for novel constructs, and our collaborator Dr. Conti providing expertise in clinical imaging. Our outside collaborators are outstanding and essential;Dr. Gillies for protein engineering, Dr. Meares for chelate chemistry and anti-chelate antibodies and Dr. Reisfeld for his tremendous expertise in immunology. This application is also notable for its use of cutting edge technologies;CEA transgenic mice for the immunotherapy projects, molecularly targeted immunotherapeutics, advanced imaging for both animal and clinical studies, nanoparticles for both radiosensitization and immunotherapy, high throughput screening to discover new constructs, a licensed cGMP compliant biologies production facility, and the newly established Clinical Immunology Correlates Support Laboratory headed by Dr. Kalos. This is all taking place in the setting of the newly established Division of Cancer Immunotherapeutics &Tumor Immunology, with a commitment from the City of Hope to build a new $60M facility by summer 2008 which will house most of the Program Project Team.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA043904-21
Application #
8331264
Study Section
Special Emphasis Panel (ZCA1-RPRB-J (M1))
Program Officer
Song, Min-Kyung H
Project Start
1998-09-18
Project End
2014-06-30
Budget Start
2012-08-23
Budget End
2014-06-30
Support Year
21
Fiscal Year
2012
Total Cost
$1,218,233
Indirect Cost
$427,580
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Kwok, Cheuk S; Frankel, Paul H; Lopatin, George et al. (2014) Using a single parameter to describe time-activity curves. Cancer Biother Radiopharm 29:83-6
Yazaki, Paul J; Lee, Brian; Channappa, Divya et al. (2013) A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance. Protein Eng Des Sel 26:187-93
Fonge, Humphrey; Leyton, Jeffrey V (2013) Positron emission tomographic imaging of iodine 124 anti-prostate stem cell antigen-engineered antibody fragments in LAPC-9 tumor-bearing severe combined immunodeficiency mice. Mol Imaging 12:191-202
Povoski, Stephen P; Davis, Paul D; Colcher, David et al. (2013) Single molecular weight discrete PEG compounds: emerging roles in molecular diagnostics, imaging and therapeutics. Expert Rev Mol Diagn 13:315-9
Barat, Bhaswati; Kenanova, Vania E; Olafsen, Tove et al. (2011) Evaluation of two internalizing carcinoembryonic antigen reporter genes for molecular imaging. Mol Imaging Biol 13:526-35
Olafsen, Tove; Wu, Anna M (2010) Antibody vectors for imaging. Semin Nucl Med 40:167-81
Kenanova, Vania E; Olafsen, Tove; Salazar, Felix B et al. (2010) Tuning the serum persistence of human serum albumin domain III:diabody fusion proteins. Protein Eng Des Sel 23:789-98
Leyton, Jeffrey V; Olafsen, Tove; Sherman, Mark A et al. (2009) Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors. Protein Eng Des Sel 22:209-16
Shibata, Stephen; Raubitschek, Andrew; Leong, Lucille et al. (2009) A phase I study of a combination of yttrium-90-labeled anti-carcinoembryonic antigen (CEA) antibody and gemcitabine in patients with CEA-producing advanced malignancies. Clin Cancer Res 15:2935-41
Gagnon, Pete; Cheung, Chia-Wei; Yazaki, Paul J (2009) Reverse calcium affinity purification of Fab with calcium derivatized hydroxyapatite. J Immunol Methods 342:115-8

Showing the most recent 10 out of 105 publications